Cord blood study could unlock new HHT treatments
NCT ID NCT05632484
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This study collected umbilical cord blood and tissue from 16 newborns who have a parent with hereditary hemorrhagic telangiectasia (HHT), a genetic disorder causing abnormal blood vessels. Researchers aim to grow and compare endothelial cells from these babies with cells from healthy donors to find differences in gene expression. The goal is to identify new targets for future HHT therapies.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
What this could lead to
If successful, this research could identify new drug targets for hereditary hemorrhagic telangiectasia (HHT), potentially leading to better treatments.
What could go wrong
This is a very small, early-stage lab study (16 participants) focused on cell collection and gene analysis, not a treatment trial. It may not directly lead to therapies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEREDITARY HAEMORRHAGIC TELANGIECTASIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hôpital Estaing
Clermont-Ferrand, 63100, France
-
Hôpital Femme-mère-Enfant
Bron, 69677, France
-
Hôpital St Eloi
Montpellier, 34295, France